CLDN1 and gastrointestinal stromal tumor: Thus, our data revealed that the inhibition of CLDN1 signaling in IM-resistant GIST re-sensitizes them to IM in vivo, thereby illustrating a novel mechanism contributing to GIST resistance to this first-line targeted drug.